Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions

Roxane Laboratories30 enrolled

Overview

The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Bipolar Disorder

Interventions

LithiumDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 38 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: * Positive test for HIV, Hepatitis B, or Hepatitis C. * Treatment with known enzyme altering drugs. * History of allergic or adverse response to lithium, or any comparable or similar product.

Locations (1)

Novum Pharmaceutical Research Services, 11248 Wilcrest Green, , Houston77042

Houston, Texas, United States

Outcomes

Primary Outcomes

Bioequivalence

Time frame: Baseline, Two period, Fourteen day washout

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.